Maguen Ezra, Morgan Margie A
Division of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Cornea. 2007 Feb;26(2):223-4. doi: 10.1097/01.ico.0000243957.29898.13.
To describe what is, to our knowledge, the first documented case of vancomycin-resistant enterococcus (VRE) conjunctivitis and its successful topical treatment.
A 77-year-old white man with end-stage multiple myeloma was hospitalized for congestive heart failure and pneumonia. During hospitalization, the patient developed conjunctivitis. Cultures of the eye were directly plated into several media. The bacterium was tested for antibiotic minimum inhibitory concentration (MIC) with the Clinical and Laboratory Standards Institute (CLSI) method.
Culture of the affected eye grew Enterococcus faecalis resistant to vancomycin. Topical treatment with moxifloxacin 0.5% (Vigamox; Alcon, Ft. Worth, TX) resulted in clinical resolution despite a MIC showing resistance.
Clinical resolution of VRE conjunctivitis was shown with topical moxifloxacin therapy in this case. At the same time, we suggest the use of combined topical and systemic therapy for treatment of VRE in immunocompromised patients.
据我们所知,描述首例有记录的耐万古霉素肠球菌(VRE)性结膜炎病例及其成功的局部治疗。
一名77岁的晚期多发性骨髓瘤白人男性因充血性心力衰竭和肺炎住院。住院期间,该患者患上了结膜炎。眼部培养物直接接种到几种培养基中。采用临床和实验室标准协会(CLSI)方法对该细菌进行抗生素最低抑菌浓度(MIC)检测。
患眼培养出对万古霉素耐药的粪肠球菌。尽管MIC显示耐药,但局部使用0.5%莫西沙星(维莫星;爱尔康公司,得克萨斯州沃思堡)治疗后临床症状消退。
本病例中局部使用莫西沙星治疗显示VRE性结膜炎临床症状消退。同时,我们建议对免疫功能低下患者的VRE感染采用局部和全身联合治疗。